Withdrawal of long-term physiological growth hormone (GH) administration: Differential effects on bone density and body composition in men with adult-onset GH deficiency

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 3, 2000, Pages 970-976

  Biller, Beverly M K ^a   Sesmilo, Gemma ^a   Baum, Howard B A ^b   Hayden, Douglas ^a   Schoenfeld, David ^a   Klibanski, Anne ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN GROWTH HORMONE;

ADULT; ARTICLE; BODY COMPOSITION; BONE DENSITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GROWTH HORMONE DEFICIENCY; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPOPITUITARISM; MALE; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

ADULT; AGE OF ONSET; BODY COMPOSITION; BONE DENSITY; DENSITOMETRY, X-RAY; GROWTH HORMONE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS;

EID: 0034453773     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.85.3.970     Document Type: Article

References (52)

1. Body composition in adult growth hormone-deficient men, assessed by anthropometry and bioimpedance analysis
2. Body composition in growth hormone-deficient adults
3. Increased body fat mass and decreased extracellular fluid volume in adults with growth hormone deficiency
4. Body composition, bone metabolism, and heart structure and function in growth hormone-deficient adults before and after GH replacement therapy at low doses
5. Adults with growth hormone deficiency have abnormal body composition but normal energy metabolism
6. Resting metabolic rate, body composition and related hormonal parameters in growth hormone-deficient adults before and after growth hormone replacement therapy
7. Abnormal body composition and reduced bone mass in growth hormone deficient hypopituitary adults
8. Increased prevalence of osteoporosis and arteriosclerosis in patients with conventionally substituted pituitary insufficiency: Is there a need for additional growth hormone substitution?
9. The bone mineral density in acquired growth hormone deficiency correlates with circulating insulin-like growth factor
10. Reduced bone mineral density in adults with growth hormone deficiency: Increased bone turnover during 12 months of GH substitution
11. Low bone mineral density in adults with previous hypothalamic-pituitary tumors; correlation with GH responses to GHRH, IGF-I and IGFBP-3
12. Reduced bone mineral content in adult patients with growth hormone deficiency
13. Reduced bone mineral density in patients with adult onset growth hormone deficiency
14. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism
15. Increased fracture frequency in adult patients with hypopituitarism and GH deficiency
16. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency
17. Growth hormone treatment of adults with growth hormone deficiency: Results of a 13-month placebo controlled cross-over study
18. The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis as well as body composition
19. Treatment of adults with growth hormone deficiency with recombinant human GH
20. Three years of growth hormone treatment in growth hormone-deficient adults: Near normalization of body composition and physical performance
21. Replacement therapy with biosynthetic human growth hormone in growth hormone deficient hypopituitary adults
22. Effect of growth hormone replacement on bone mass in adults with adult onset growth hormone deficiency
23. Adult growth hormone deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment
24. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset of growth hormone deficiency. A randomized, placebo-controlled trial
25. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency
26. Long-term change in the bone mineral density of adults with adult onset growth hormone (GH) deficiency in response to short or long-term GH replacement therapy
27. Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone (GH) in patients with adult-onset GH deficiency
28. Effect of long-term treatment with GH on bone metabolism, bone mineral density and bone elasticity in GH-deficient adults
29. Effects of long-term growth-hormone substitution therapy on bone mineral density and parameters of bone metabolism in adult patients with growth hormone deficiency
30. Gender diferences in the effects of long term growth hormone (GH) treatment on bone in adults with GH deficiency
31. Effects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults
32. Effects of physiological growth hormone (GH) therapy on cognition and quality of life in patients with adult-onset GH deficiency
33. Changes in skeletal muscle and body composition after discontinuation of growth hormone treatment in growth hormone deficient young adults
34. Discontinuation of growth hormone therapy in growth-hormone-deficient patients: Assessment of body fat mass using bioelectrical impedance
35. Changes in body composition and bone density after discontinuation of growth hormone therapy in adolescence: An interim report
36. Long-term prospective study of body composition and lipid profiles during and after growth hormone (GH) treatment in children with GH deficiency: Gender-specific metabolic effects
37. Effects of growth hormone (GH) replacement on bone metabolism and mineral density in adult onset of GH deficiency: Results of a double-blind placebo-controlled study with open follow-up
38. Elderly patients with adult-onset growth hormone deficiency are not osteopenic
39. Preliminary study of the effects of growth hormone substitution therapy on bone mineral density and serum osteocalcin levels in adult growth hormone deficiency
40. Growth hormone treatment in adults with GH deficiency: Effects on new biochemical markers of bone and collagen turnover
41. Short and long-term effects of growth hormone treatment on bone turnover and bone mineral content in adult growth hormone-deficient males
42. The effect of growth hormone replacement therapy in hypopituitary adults on calcium and bone metabolism
43. The effects of prolonged growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults
44. Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: A double blind, randomized, placebo-controlled study
45. Increased bone density after recombinant human growth hormone therapy in adults with isolated GH deficiency
46. Growth hormone and bone
47. Gender differences in insulin-like growth factor and bone mineral density association in old age: The Rancho Bernardo study
48. Low dose recombinant human growth hormone normalizes bone metabolism and cortical bone density and improves trabecular bone density in growth hormone deficient adults without causing adverse effects
49. Further increase in forearm cortical bone mineral content after discontinuation of growth hormone replacement
50. A short course of recombinant human growth hormone treatment stimulates osteoblasts and activates bone remodeling in normal human volunteers
51. Effects of short term insulin-like growth factor-I (IGF-I) or growth hormone (GH) treatment on bone metabolism and on production of 1,25-dihydroxycholecalciferol in GH-deficient adults
52. Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis